Cholesterol Injection Schedules: Twice-Yearly Dosing for Seniors
Inclisiran needs just two shots a year after the initial doses, easing adherence for adults 65+ with no added safety risk versus younger patients.
Inclisiran
28 source-based articles maintained by the HealthRX.com Editorial Team.
28articles
6topic areas covered
May 26, 2026latest review
Inclisiran library
Showing 28 of 28 clinical reviews.
Does Humana Cover Leqvio (Inclisiran)? Coverage, Prior Auth, and Appeals Guide
A guide to Humana coverage of Leqvio (inclisiran) for ASCVD and familial hypercholesterolemia, including formulary tiers, prior-authorization criteria, step-therapy requirements, and how to appeal a denial.
Does TRICARE Cover Leqvio (Inclisiran)? Prior Authorization, Formulary Tier, and Appeal Steps
TRICARE covers Leqvio (inclisiran) for ASCVD and familial hypercholesterolemia with prior authorization. Learn formulary tier, step-therapy requirements, appeal steps, and out-of-pocket costs for military beneficiaries.
How to Prepare Leqvio Injection, Step by Step
Leqvio (inclisiran) is a twice-yearly subcutaneous injection cutting LDL-C about 50%. Here's the step-by-step self-injection prep and technique for home use.
Inclisiran (Leqvio) During Pregnancy and Lactation: What the Evidence Actually Shows
A source-checked look at what is and is not known about inclisiran (Leqvio) safety in pregnancy and breastfeeding, based on FDA labeling, animal reproductive toxicology data, and current lipid-management guidelines.
Leqvio (Inclisiran) and Autoimmune Disease: What Clinicians Need to Know
A clinical deep-dive into inclisiran (Leqvio) use in patients with autoimmune disease, covering safety data from ORION trials, immunogenicity findings, dosing considerations, and practical guidance for rheumatology-cardiology co-management.
Leqvio (Inclisiran) Cost vs Other Lipid-Lowering Therapies
Leqvio costs about $6,500-$7,000/year, similar to evolocumab and alirocumab, with two doses yearly vs monthly injections; final cost depends on payer rebates.
Leqvio (Inclisiran) Food & Supplement Interactions: What Patients Need to Know
A guide to inclisiran (Leqvio) food and supplement interactions, covering mechanism of action, known drug-nutrient interactions, and practical dietary guidance for patients on twice-yearly PCSK9 siRNA therapy.
Leqvio (Inclisiran) Long-Term Cardiovascular Benefits
LDL-C stays down about 50% at 17 months in ORION-10/11, but proof it cuts heart attacks and strokes awaits ORION-4 results through 2026.
Leqvio (Inclisiran) Manufacturing, Supply, and Shortage History
A clinical overview of Leqvio (inclisiran) manufacturing processes, supply chain logistics, shortage history, and current availability status for prescribers and patients.
Leqvio (Inclisiran) Monitoring for Adults Aged 30, 49: Lab Schedules, Safety Checks, and Follow-Up
Evidence-based monitoring guide for inclisiran (Leqvio) in adults aged 30 to 49, covering lipid panels, liver function tests, injection-site checks, and long-term follow-up schedules.
Leqvio (Inclisiran) Renal Protection or Renal Risk: What the Evidence Shows
A current, source-checked review of inclisiran in chronic kidney disease: FDA renal dosing, ORION-7 pharmacokinetics, 2026 pooled CKD data, and the limits of renal-outcome evidence.
Leqvio (Inclisiran) Safety Profile in Adults Aged 30-49
ORION trial data show Leqvio safety comparable to placebo, with injection-site reactions in ~5% of patients and 50% sustained LDL-C reduction.
Leqvio (Inclisiran) Storage, Stability & Shelf Life: What Clinicians and Patients Need to Know
Evidence-based guide to inclisiran (Leqvio) storage requirements, thermal stability data, shelf life, and handling best practices. Includes FDA labeling details and clinic-level decision guidance.
Leqvio (Inclisiran) Switching Protocols: How to Transition From or To Other LDL-Lowering Drugs
A clinician-level guide to switching between inclisiran (Leqvio) and other LDL-lowering therapies including PCSK9 monoclonal antibodies, statins, and ezetimibe. Covers mechanism, timing, washout considerations, and dosing schedules backed by ORION trial data.
Leqvio (Inclisiran): How to Safely Stop
A guide to discontinuing inclisiran (Leqvio), covering LDL rebound timelines, bridging strategies, cardiovascular risk management, and when stopping is medically appropriate.
Leqvio Cancer Risk Signal Review: What the Clinical Data Actually Show
A physician-level review of the inclisiran (Leqvio) cancer risk signal: ORION trial data, FDA labeling, post-marketing surveillance, and how to counsel patients with ASCVD or familial hypercholesterolemia.
Leqvio Cognitive Function Impact: What the Evidence Actually Shows
A clinical deep-dive into inclisiran (Leqvio) and cognitive function. Covers ORION trial data, PCSK9 inhibitor cognitive safety evidence, FDA labeling, and how to counsel patients asking whether Leqvio affects memory or thinking.
Leqvio EMA Approval and Regulatory Status vs US, UK, Canada
EMA approved Leqvio (inclisiran) for LDL-C lowering, like the FDA, Health Canada, and NICE, all without proven cardiovascular outcomes data yet.
Leqvio Hair and Skin Changes: What the Evidence Can Show
What evidence shows about Leqvio hair loss and skin changes, how to track symptoms, and when patchy loss or allergic symptoms need attention.
Leqvio Lab Timing: When to Test Before Each Dose
Leqvio labs: fasting lipid panel before each of the first 3 doses, plus ALT/AST at baseline and 3 months. Full schedule for ages 18-29 inside.
Leqvio Liver Function Impact: What Inclisiran Does (and Does Not Do) to Your Liver
A clinician-level review of inclisiran (Leqvio) liver function impact, covering ALT/AST data from ORION-10, ORION-11, and ORION-3, hepatic metabolism, and what to monitor before and after dosing.
Leqvio Long-Term Safety: What Clinical Trials Show
ORION-10 and ORION-11 found serious adverse events similar to placebo, with injection-site reactions as the main mild, self-limited signal in long-term use.
Leqvio Missed-Dose Protocol: What to Do If You Miss an Inclisiran Injection
Complete clinical guide to the Leqvio (inclisiran) missed-dose protocol, including how the drug works, what happens when a dose is delayed, and exactly when to reschedule.
Leqvio Patent Field & Generic Timeline: When Will Inclisiran Go Generic?
A breakdown of Leqvio (inclisiran) patents, FDA exclusivity, ORION trial data, mechanism of action, and the realistic generic entry timeline for this twice-yearly PCSK9 siRNA.
Leqvio Safety Signals & FDA Actions: What Clinicians and Patients Need to Know
A comprehensive analysis of inclisiran (Leqvio) safety signals, FDA actions, post-market surveillance data, mechanism of action, and clinical trial evidence from ORION-10 and ORION-11.
Leqvio Travel & Timezone-Shift Protocols: Complete Clinical Guide
Everything clinicians and patients need to know about timing Leqvio (inclisiran) doses around travel, timezone changes, and real-world scheduling. MD/PharmD-level depth with primary-literature citations.
Leqvio Twice-Yearly Dosing Schedule (Official FDA Regimen)
Leqvio dosing is 284 mg at day 0, month 3, then every 6 months for all adults, including ages 50 to 64. No age-based dose adjustment is specified.